2009-11-24 07:12:04 -

London, November , 24, 2009

Oslo, Norway, 24 November 2009

Clavis Pharma ASA (OSE: CLAVIS), the clinical stage oncology focused
pharmaceutical company, announced today a $380 million agreement for
the further development and commercialisation of its drug candidate,
CP-4126, currently in Phase II development in pancreatic cancer.

A meeting for investors, analysts and press will take place in Oslo
at 10.00 CET today, 24 November 2009 at Hotel Continental,
Stortingsgaten 24, Oslo, Norway.


An international conference call will take place at 12:00 CET -
details are given below.

Access the audio for the meeting by dialling the following and
quoting confirmation code 4956336 :

+47 2415 9758 (from Norway)
+44 (0)20 7806 1966 (International)

For visuals click on the direct access link:

www.livemeeting.com/cc/premconfeurope/join?id=4956336&role=atten ..


Participating in the Meeting and Conference Call will be:

Geir Christian Melen, CEO, Clavis Pharma ASA
Keith McCullagh, Chairman, Clavis Pharma ASA
Patrick Mahaffy, President & CEO, Clovis Oncology Inc.

The presentation will be made available on www.clavispharma.com in
the Investors section from 09:00 CET. A webcast of the conference
call will be available from Clavis Pharma's website,
www.clavispharma.com for a period of 30 days.

For Further Information Contact:

Geir Christian Melen
Chief Executive Officer
+47 24 11 09 50
+47 91 30 29 65 (mob)
geir.christian.melen@clavispharma.com

Gunnar Manum
Chief Financial Officer
+47 24 11 09 71
+47 95 17 91 90 (mob)
gunnar.manum@clavispharma.com
Mark Swallow / Nina Enegren / David Dible
Citigate Dewe Rogerson
+44 207 282 2948
clavispharma@citigatedr.co.uk


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.